LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 52

Search options

  1. Article ; Online: In-Hospital Use of PCSK9 Inhibitors in the Post ACS Patient: What Does the Evidence Show?

    Canonico, Mario Enrico / Hess, Connie N / Cannon, Christopher P

    Current atherosclerosis reports

    2023  Volume 25, Issue 7, Page(s) 381–389

    Abstract: Purpose of review: The purpose of this review is to analyze and discuss the most recent data on in hospital prescription of Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) inhibitors in patients with acute coronary syndrome (ACS).: Recent findings: ... ...

    Abstract Purpose of review: The purpose of this review is to analyze and discuss the most recent data on in hospital prescription of Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) inhibitors in patients with acute coronary syndrome (ACS).
    Recent findings: Recent randomized clinical trials (RTCs) have demonstrated a beneficial effect of monoclonal antibodies (mAb) PCSK9i prescription in patients with ACS on rapid reduction of low-density lipoprotein cholesterol (LDL-C) and on coronary atherosclerosis assessed by intracoronary imaging. Additionally, the safety profile of mAb PCSK9i was confirmed in all RTCs. Available RCTs show the effectiveness and rapid achievement of LDL-C levels according to American College of Cardiology/American Heart Association and European Society of Cardiology guidelines for ACS patients. However, RCTs addressing cardiovascular outcomes of PCSK9i in-hospital initiation in ACS patients are currently ongoing.
    MeSH term(s) United States ; Humans ; Proprotein Convertase 9 ; PCSK9 Inhibitors ; Cholesterol, LDL ; Subtilisin/therapeutic use ; Acute Coronary Syndrome/drug therapy ; Proprotein Convertases/therapeutic use ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Monoclonal/pharmacology ; Anticholesteremic Agents/therapeutic use ; Anticholesteremic Agents/pharmacology ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use
    Chemical Substances PCSK9 protein, human (EC 3.4.21.-) ; Proprotein Convertase 9 (EC 3.4.21.-) ; PCSK9 Inhibitors ; Cholesterol, LDL ; Subtilisin (EC 3.4.21.62) ; Proprotein Convertases (EC 3.4.21.-) ; Antibodies, Monoclonal ; Anticholesteremic Agents ; Hydroxymethylglutaryl-CoA Reductase Inhibitors
    Language English
    Publishing date 2023-05-24
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 2057369-8
    ISSN 1534-6242 ; 1523-3804
    ISSN (online) 1534-6242
    ISSN 1523-3804
    DOI 10.1007/s11883-023-01112-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Sex differences in guideline-directed medical therapy in 2021-22 among patients with peripheral artery disease.

    Canonico, Mario Enrico / Hsia, Judith / Hess, Connie N / Bonaca, Marc P

    Vascular medicine (London, England)

    2023  Volume 28, Issue 3, Page(s) 233–235

    MeSH term(s) Humans ; Male ; Female ; Sex Characteristics ; Peripheral Arterial Disease/diagnosis ; Peripheral Arterial Disease/drug therapy ; Risk Factors
    Language English
    Publishing date 2023-02-27
    Publishing country England
    Document type Letter
    ZDB-ID 1311628-9
    ISSN 1477-0377 ; 1358-863X
    ISSN (online) 1477-0377
    ISSN 1358-863X
    DOI 10.1177/1358863X231155308
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Updates in the management of cancer therapy-related hypertension.

    Gupta, Prerna / Canonico, Mario Enrico / Faaborg-Andersen, Christian / Prabhu, Nicole / Kondapalli, Lavanya / Quintana, Raymundo A

    Current opinion in cardiology

    2024  

    Abstract: Purpose of review: To provide a comprehensive review of hypertension among patients with cancer. Several cancer therapies cause hypertension which has resulted in a growing and vulnerable population of patients with difficult to control hypertension ... ...

    Abstract Purpose of review: To provide a comprehensive review of hypertension among patients with cancer. Several cancer therapies cause hypertension which has resulted in a growing and vulnerable population of patients with difficult to control hypertension which has significant downstream effects.
    Recent findings: Hypertension affects up to 50% of cancer patients and higher comorbidity when compared to the general population. Many anticancer therapies can cause hypertension through their treatment effect. Antihypertensive treatment is crucial given cardiovascular mortality is a leading cause of death among cancer patients. It is already known that hypertension is poorly controlled in the general population, and there are additional challenges in management among patients with cancer. Patients with cancer suffer from multimorbidity, are on multiple medications creating concern for drug interactions, and often have blood pressure lability, which can worsen clinical inertia among patients and their providers. It is crucial to effectively treat hypertension in cancer patients to mitigate downstream adverse cardiovascular events.
    Summary: In recent years, there have been significant changes in management guidelines of hypertension and simultaneously as influx of new cancer therapeutics. We provide an update on hypertension treatment among patients with cancer on different chemotherapeutic agents.
    Language English
    Publishing date 2024-02-26
    Publishing country United States
    Document type Journal Article
    ZDB-ID 645186-x
    ISSN 1531-7080 ; 0268-4705
    ISSN (online) 1531-7080
    ISSN 0268-4705
    DOI 10.1097/HCO.0000000000001127
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Uptake of Newer Guideline-Directed Therapies in Heart Failure Patients With Diabetes or Chronic Kidney Disease.

    Canonico, Mario Enrico / Hsia, Judith / Cannon, Christopher P / Bonaca, Marc P

    JACC. Heart failure

    2022  Volume 10, Issue 12, Page(s) 989–991

    MeSH term(s) Humans ; Heart Failure/complications ; Heart Failure/therapy ; Diabetes Mellitus ; Renal Insufficiency, Chronic/complications ; Renal Insufficiency, Chronic/therapy
    Language English
    Publishing date 2022-11-09
    Publishing country United States
    Document type Letter
    ZDB-ID 2705621-1
    ISSN 2213-1787 ; 2213-1779
    ISSN (online) 2213-1787
    ISSN 2213-1779
    DOI 10.1016/j.jchf.2022.09.013
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article: Drug-drug interactions between antithrombotics and direct-acting antivirals in hepatitis C virus (HCV) patients: A brief, updated report.

    Canonico, Mario Enrico / Sanna, Giuseppe Damiano / Siciliano, Roberta / Scudiero, Fernando / Esposito, Giovanni / Parodi, Guido

    Frontiers in pharmacology

    2022  Volume 13, Page(s) 916361

    Abstract: Hepatitis C virus (HCV) is one of the leading causes of chronic liver disease affecting over 71 million people worldwide. An increased incidence of atherothrombotic events [e.g. coronary artery disease (CAD), atrial fibrillation (AF)] has been observed ... ...

    Abstract Hepatitis C virus (HCV) is one of the leading causes of chronic liver disease affecting over 71 million people worldwide. An increased incidence of atherothrombotic events [e.g. coronary artery disease (CAD), atrial fibrillation (AF)] has been observed in HCV seropositive patients. On the other hand, an increased bleeding risk is another clinical issue, particularly in subjects with liver cirrhosis, gastroesophageal varices, portal hypertension, thrombocytopenia and alcohol consumption. The introduction and progressively greater use of direct-acting antivirals (DAAs) (instead of protease and polymerase inhibitors) during the last decade has enabled a sustained virological response to be achieved in a significant percentage of patients. However, due to the high cardiovascular risk profile in HCV-infected patients, the concomitant use of antithrombotic therapies is often required, bearing in mind the possible contraindications. For example, despite better pharmacokinetic and pharmacodynamic properties compared with vitamin K-antagonists, plasma level fluctuations of direct oral anticoagulants (DOACs) due to pathological conditions (e.g. chronic kidney diseases or hepatic cirrhosis) or drug-drug interactions (DDIs) may be of great importance as regards their safety profile and overall clinical benefit. We aimed to examine and briefly summarize the significant DDIs observed between antithrombotic and HCV antiviral drugs.
    Language English
    Publishing date 2022-08-09
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2587355-6
    ISSN 1663-9812
    ISSN 1663-9812
    DOI 10.3389/fphar.2022.916361
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Systematic basic and advanced resuscitation training in medical students and fellows: a proposal from the Working Group on Cardiovascular Urgences and Emergencies of the Italian Society of Cardiology.

    Saba, Pier Sergio / Canonico, Mario Enrico / Gambaro, Alessia / Gazale, Giovanni / Piga, Stefania / Santomauro, Maurizio / Roscio, Giancarlo

    Journal of cardiovascular medicine (Hagerstown, Md.)

    2023  Volume 24, Issue Suppl 2, Page(s) e128–e133

    Abstract: Sudden cardiac arrest is a leading cause of death in Europe. High-quality cardiopulmonary resuscitation (CPR) and guidelines compliance of rescuers have been associated with better outcomes after cardiac arrest. However, wide variability in attempting ... ...

    Abstract Sudden cardiac arrest is a leading cause of death in Europe. High-quality cardiopulmonary resuscitation (CPR) and guidelines compliance of rescuers have been associated with better outcomes after cardiac arrest. However, wide variability in attempting bystander CPR manoeuvres has been reported. Educational programmes for teaching CPR to medical students and fellows are highly advisable in this context. However, there is no homogeneity regarding the CPR education offered by academic institutions. We surveyed 208 Italian medical students and 162 fellows in cardiology regarding the educational offer and needs in CPR. Among the 11 medical schools surveyed, 8 (73%) offer basic (BLS) courses but only 3 (38%) with formal certification of 'BLS provider', while none offers advanced (ACLS/ALS) courses. Among the 30 specialization schools in cardiology surveyed, 10 (33%) offer a BLS course (6 with formal certification of 'BLS provider'), and 8 (27%) offer an ACLS/ALS course (5 with formal certification). Only a minority of students and fellows perceive themselves as highly proficient either in BLS or ACLS/ALS, although most of the fellows were involved at least once in rescuing a cardiac arrest. The present position paper analyses and suggests the strategies that should be adopted by Italian medical and specialization schools to spread the CPR culture and increase the long-standing retention of CPR-related technical and nontechnical skills.
    MeSH term(s) Humans ; Cardiology/education ; Cardiopulmonary Resuscitation/education ; Emergencies ; Heart Arrest/therapy ; Italy ; Students, Medical
    Language English
    Publishing date 2023-05-03
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2223461-5
    ISSN 1558-2035 ; 1558-2027
    ISSN (online) 1558-2035
    ISSN 1558-2027
    DOI 10.2459/JCM.0000000000001421
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Balloon Angioplasty of the Radial Artery to Solve a Challenging Radial Sheath Insertion.

    Talanas, Giuseppe / Guarino, Simona / Canonico, Mario Enrico / Parodi, Guido

    The Journal of invasive cardiology

    2020  Volume 33, Issue 1, Page(s) E69

    Abstract: The inability to advance the dedicated wire of the transradial sheath in a radial artery with a good pulsatile blood flow is a very rare event. In this case, the advancement of a high-performance 0.014 inch coronary wire is the only option to gain the ... ...

    Abstract The inability to advance the dedicated wire of the transradial sheath in a radial artery with a good pulsatile blood flow is a very rare event. In this case, the advancement of a high-performance 0.014 inch coronary wire is the only option to gain the vessel. Then, if the transradial sheath is stuck in the proximal radial artery wall, balloon angioplasty of the radial artery may allow successful reinsertion of the transradial sheath. This technique allows the preservation of radial artery access, avoiding a shift to an alternative arterial approach.
    MeSH term(s) Angioplasty, Balloon ; Angioplasty, Balloon, Coronary ; Coronary Angiography ; Humans ; Radial Artery/surgery
    Language English
    Publishing date 2020-12-07
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1154372-3
    ISSN 1557-2501 ; 1042-3931
    ISSN (online) 1557-2501
    ISSN 1042-3931
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Intrappolamento di guida coronarica e rimozione non intenzionale di stent appena impiantato.

    Talanas, Giuseppe / Siciliano, Roberta / Canonico, Mario Enrico / Parodi, Guido

    Giornale italiano di cardiologia (2006)

    2020  Volume 21, Issue 11 Suppl 1, Page(s) 58S–59S

    Abstract: A 53-year-old male was admitted to our department for unstable angina. Coronary angiography showed a subocclusive stenosis in the ostial-proximal tract of an intermediate branch in the context of a left dominance system. We proceeded with an ad hoc ... ...

    Title translation Coronary wire entrapment and unintended extraction of a just deployed stent.
    Abstract A 53-year-old male was admitted to our department for unstable angina. Coronary angiography showed a subocclusive stenosis in the ostial-proximal tract of an intermediate branch in the context of a left dominance system. We proceeded with an ad hoc percutaneous coronary intervention considering this intermediate branch lesion in the setting of a bifurcation (Medina 0,0,1), where the proximal and distal main branches were represented by the left main and left anterior descending (LAD) arteries, respectively. After pre-dilation of the intermediate branch lesion, we advanced a "safety balloon" in order to protect the LAD branch and, simultaneously, we deployed a 3.0/22 mm drug-eluting stent in the intermediate branch. After in-stent post-dilation, we felt a strong resistance during the guidewire removal from the LAD indicating a wire entrapment. After a vigorous traction of the jailed guidewire, we observed the accidental removal of the just deployed stent from the guiding catheter. We re-advanced a guidewire on the LAD and a 3.25/23 mm drug-eluting stent was successfully implanted on the intermediate branch. We briefly discuss the occurred complication and some technical aspects regarding this case.
    MeSH term(s) Coronary Angiography ; Coronary Stenosis/diagnostic imaging ; Coronary Stenosis/surgery ; Coronary Vessels/diagnostic imaging ; Coronary Vessels/surgery ; Drug-Eluting Stents/adverse effects ; Humans ; Male ; Middle Aged ; Percutaneous Coronary Intervention ; Stents/adverse effects ; Treatment Outcome
    Language Italian
    Publishing date 2020-12-09
    Publishing country Italy
    Document type Case Reports ; Journal Article
    ZDB-ID 2272414-X
    ISSN 1972-6481 ; 1827-6806
    ISSN (online) 1972-6481
    ISSN 1827-6806
    DOI 10.1714/3487.34674
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: The tug-of-war between coagulopathy and anticoagulant agents in patients with COVID-19.

    Canonico, Mario Enrico / Siciliano, Roberta / Scudiero, Fernando / Sanna, Giuseppe Damiano / Parodi, Guido

    European heart journal. Cardiovascular pharmacotherapy

    2020  Volume 6, Issue 4, Page(s) 262–264

    MeSH term(s) Anticoagulants ; Betacoronavirus ; COVID-19 ; Coronavirus ; Coronavirus Infections ; Humans ; Pandemics ; Pneumonia, Viral ; SARS-CoV-2
    Chemical Substances Anticoagulants
    Keywords covid19
    Language English
    Publishing date 2020-05-26
    Publishing country England
    Document type Letter ; Comment
    ZDB-ID 2808613-2
    ISSN 2055-6845 ; 2055-6837
    ISSN (online) 2055-6845
    ISSN 2055-6837
    DOI 10.1093/ehjcvp/pvaa048
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Platelet inhibition with orodispersible ticagrelor in acute coronary syndromes according to morphine use: the TASTER study final results.

    Parodi, Guido / Dossi, Filippo / Raccis, Mario / Talanas, Giuseppe / Mura, Enrico / Siciliano, Roberta / Guarino, Simona / Marini, Alessandro / Franca, Paolo / Saba, Pier Sergio / Sanna, Giuseppe D / Canonico, Mario E

    European heart journal. Cardiovascular pharmacotherapy

    2023  Volume 9, Issue 8, Page(s) 692–700

    Abstract: Aim: To date, it is still unknown whether orodispersible tablet (ODT) ticagrelor might represent a suitable way to reach a proper antiaggregation in acute coronary syndrome (ACS) patients receiving morphine. Aim of the present study was to evaluate ... ...

    Abstract Aim: To date, it is still unknown whether orodispersible tablet (ODT) ticagrelor might represent a suitable way to reach a proper antiaggregation in acute coronary syndrome (ACS) patients receiving morphine. Aim of the present study was to evaluate platelet inhibition with 180 mg ticagrelor loading dose (LD) administered as ODT compared with standard coated tablet ticagrelor formulation in ACS patients undergoing percutaneous coronary intervention (PCI) according to morphine use.
    Methods and results: One-hundred and 30 patients presenting with STEMI or very high-risk NSTE-ACS were randomly assigned to receive ODT or standard ticagrelor LD. Potential morphine-ticagrelor interaction was assessed by stratified randomization according to morphine use. Platelet reactivity was evaluated by Platelet Reactivity Units (PRU) VerifyNow™ 1, 2, 4, and 6 h after ticagrelor LD. The primary endpoint was residual platelet reactivity 1 h after LD across the two ticagrelor formulation and according to morphine use. Safety endpoints were major bleedings and other in-hospital ticagrelor administration-related adverse events. One hour after LD, PRU median value was higher in morphine-treated patients (N = 32) as compared with patients not receiving morphine (N = 98; PRU = 187 [70-217]) vs. 73 [7-187]; P = 0.012). In patients with morphine, 1-h PRU values were similar between study groups (192 [114-236] vs. 173 [16-215] in ODT and standard tablet ticagrelor, respectively). Similarly, in patients without morphine, 1-h PRU values were not significantly different between study groups (69 [8-152] vs. 110 [6-193] in ODT and standard tablet ticagrelor, respectively). Platelet reactivity appeared similar in the 2 study arms at 2, 4, and 6 h after LD. No significant difference was observed among patients with or without morphine regarding in-hospital adverse events or drug side-effects, even if a reinfarction due to acute stent thrombosis was observed in a patient treated with morphine.
    Conclusions: There was no difference between ODT and standard ticagrelor tablets in terms of post-LD residual platelet reactivity, percentage of platelet inhibition or safety regardless to morphine use.
    MeSH term(s) Humans ; Ticagrelor/adverse effects ; Acute Coronary Syndrome/diagnosis ; Acute Coronary Syndrome/drug therapy ; Platelet Aggregation Inhibitors/adverse effects ; Percutaneous Coronary Intervention/adverse effects ; Percutaneous Coronary Intervention/methods ; Adenosine/adverse effects ; Tablets ; Morphine Derivatives
    Chemical Substances Ticagrelor (GLH0314RVC) ; Platelet Aggregation Inhibitors ; Adenosine (K72T3FS567) ; Tablets ; Morphine Derivatives
    Language English
    Publishing date 2023-08-15
    Publishing country England
    Document type Randomized Controlled Trial ; Journal Article
    ZDB-ID 2808613-2
    ISSN 2055-6845 ; 2055-6837
    ISSN (online) 2055-6845
    ISSN 2055-6837
    DOI 10.1093/ehjcvp/pvad061
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top